Meeting
2019 ASCO Annual Meeting
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).
Authors
Julie Van
Vanderbilt University Medical Center, Nashville, TN
Julie Van , David F. Penson , Alfred Rademaker , James C. Jackson , Kelvin A. Moses , Alicia K. Morgans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03016741
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5098)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5098
Abstract #
TPS5098
Poster Bd #
204a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang
Poster
2022 ASCO Genitourinary Cancers Symposium
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
First Author: Zeynep Busra Zengin